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的 NAAA 抑制剂有着重要的研究意义。但目前强有效和高选择性的 NAAA 抑制剂
还没被发现。现有文献报道的 NAAA抑制剂，都是 PPARα内源性配体 PEA的衍生




























表征。经体外 NAAA生物活性抑制实验表明，除了化合物 P23不能抑制 NAAA，
其他 17个化合物对 NAAA都有明显的抑制作用，10 µM下抑制率基本达到 50%以

















Peroxisome Proliferator-Activated Receptors (PPAR) is a class of ligand- activated 
nuclear transcription factor belonging to the nuclear receptor superfamily. PPAR play a 
key regulatory role in lipid metabolism, fat cell differentiation, glucose homeostasis 
process, and are closely related to cardiovascular disease, diabetes, obesity, lipid 
disorders, inflammation, cancer and other diseases. PPARα, PPARβ, and PPARγ are its 
three subtypes. PPARα ligands can be divided into natural ligands and synthetic ligands 
according to different sources. Natural ligands are mainly from diet and the body's 
metabolic products, such as long-chain polyunsaturated fatty acids, including oleic acid, 
linoleic acid, arachidonic acid and so on. Synthetic ligands have lipid-lowering drugs 
fibrates and some non-steroidal anti-inflammatory drugs such as phenoxy styrene-acrylic 
acid.  
There’re a large number of saturated and unsaturated N-acyl-ethanolamines NAE, 
which are long-chain fatty acid ethanolamine compounds, belonging to the endogenous 
activity of animal tissue lipid family, with small concentrations found in any organization 
of living organisms. They were found to have significant activity in the central and 
peripheral physiological functions. Oleoyl ethanolamine OEA and palmitoyl 
ethanolamine PEA are endogenous PPARα ligands. OEA controls appetite and lipid 
metabolism and regulates lipid balance by activating PPARα to achieve the purpose of 
weight loss. More recently, it’s been found that PEA could act on the central sensory 
nervous systems and immune cells with the analgesic and anti-inflammatory effects, and 
could protect the central nervous systems. However, these NAE are easily been 
hydrolyzed by N-acyl ethanolamine acid amide hydrolysis enzyme NAAA and lose 
biological activity. Therefore, looking for a strong and effective NAAA inhibitor has a 
very important significance for biological research. But, at present, the strong, effective 
and highly selective NAAA inhibitor has not been found. Structures reported as NAAA 
inhibitors are almost all of derivatives of the endogenous PPARα ligand PEA.Recently, 














with PPARα. Therefore, it can be inferred that NAAA inhibitors may be in certain 
relations with PPARα ligands. It’s important of biological significance that study 
compounds that resist enzymatic hydrolysis while retaining agonist activity at PPARα 
Such agents may not only be useful to characterize the pharmacological properties of 
NEA in live animals but might also provide a starting point for the development of novel 
antiobesity, antihyperlipidemic, and anti-inflammatory drug. 
In the case of undetermining three-dimensional structure and potent inhibit of NAAA, 
we analyze crystal structure of GW409544 and PPARα complexes and establish 
optimization solutions of docking based on the combination of the existing structure of 
PPARα agonists and experimental activity datum by using Surflex-Dock. Docking results 
show that PPARα agonists are composed by polar head and hydrophobic part and the 
flexible linker.And then virtually screen commercial small molecule libraries in consist of 
a total of 500,000 molecules. We synthesize the partial compounds of theoretical activity. 
Eighteen compounds consist of fatty acid alcohol compounds, fatty acid amide 
compounds, fatty acid ester compounds and acrylic compounds are sythesised. Their 
structures were confirmed by MS, 1H-NMR, 13C-NMR, IR and melting point tester. 
NAAA biological activity in vitro inhibition experiments show that, in addition to P23 
compound can’t inhibit NAAA, the other 17 compounds have obvious inhibitory rate of 
nearly 50% to the NAAA at 10µM, compounds P69 and P119 inhibitions on the NAAA 
are particularly high, the inhibition rates were 92.73% and 94.93%, especially compounds 
P69 and NAAA are non-covalent interactions, suggesting a strong inhibitor of the good 
value of research. 
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第一章 前 言 
1 
第一章 前 言 
   1990 年Issemann等[1]最先从小鼠肝脏中发现了一种新的甾体激素受体，它能被
一类脂肪酸样化合物过氧化物酶体增殖剂(Peroxisome Proliferators，PP)激活，而被
命名为PP激活受体(Peroxisome Proliferators Activated Receptors, PPAR)。PPAR还能













脂肪酰胺水解酶(Fatty acid amide hydrolase, FAAH) 作用下水解成相应的脂肪酸和
乙醇胺，而失去生理活性。已经证实OEA能被FAAH和另外一种N-酰基乙醇胺水解






































统和免疫细胞中的靶标[23]，是 PPARα的内源性天然配体，EC50为 3.4 µM[24]。油酰
乙醇胺 OEA 出现在所有可表达 PPARα 的组织中包括大脑，是 PPARα 高亲和力内
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3 
[30]。相反，内源效应[31,32]，则认为 PEA只是辅助 AEA的抗炎和止痛效应，AEA是
大麻受体 CB1和 CB2激动剂，经常跟 PEA 同时产生[33,34]。第三是受体机理，根据
PEA能直接激活 CB2和 PPARα能力，阐明了 PEA许多抗炎效应[37]。目前也有人发






已被克隆出来[36]。目前有四种关于 NAPE 转化为 NAEs 的学说：第一种学说：N-
酰基磷脂酰乙醇胺就是在该合成酶作用下直接生成 NAE[37]；第二种学说：一分泌型
磷脂酶 sPLA2把 NAPE水解为 N-酰基溶血磷脂酶乙醇胺（lyso-NAPE），接着被溶
血磷脂酶 D水解为 N-酰基乙醇胺 NAE[38]。第三种学说：α/β水解酶 4对甘油磷酸乙
醇胺的形成起到溶血磷脂酶/磷脂 B的作用，接着甘油磷酸乙醇胺被甘油磷酸二酯酶
GDE1水解为 N-酰基乙醇胺[39]。第四种学说：NAPE依靠 PLC途径转化为磷酸 NAE，





























能水解 PEA和 OEA，却不水解 AEA[44]。它靠自我催化水解来激活的，是靠 Asn-107，
Asn-309和 Asn-333的 N-糖酰基化稳定的[47]。NAAA是由 362（小鼠和大鼠）个或
359（人）个氨基酸残基组成。人和老鼠之间的 NAAA 有 76.5%的同源性，人和大
鼠 NAAA有 76.7%的同源性，大鼠和老鼠有 90.1%的同源性[46]。如图 1.1。 
 
图1.1  人(h)、小鼠(m)和大鼠(r)的NAAA氨基酸顺序同源性 
FAAH和 NAAA是两种不相关的酶，没有任何同源性[44]。不仅从他们的结构，
而且他们表现出来的催化活性也有很多不同点。最大的区别就是 FAAH的水解条件




合物 Triton X-100存在的条件下水解 PEA比水解其他 NAE快很多[45]。另外一个很显
著的区别就是 FAAH能水解 2-AG，而 NAAA不能水解[48]。 
1.2.2 NAAA的生理学作用 
大量有关用 FAAH缺失的小鼠来研究 FAAH降解 AEA和其他 NAE的实验，都
表明了在脑中 FAAH 起到主要作用，NAAA 起到次要作用[49]。在敲除 FAAH 的小
鼠脑中的 AEA、OEA和 PEA的内源水平是在没敲除 FAAH中的含量 10-39倍[49]。
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